JP2020515257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515257A5 JP2020515257A5 JP2019553050A JP2019553050A JP2020515257A5 JP 2020515257 A5 JP2020515257 A5 JP 2020515257A5 JP 2019553050 A JP2019553050 A JP 2019553050A JP 2019553050 A JP2019553050 A JP 2019553050A JP 2020515257 A5 JP2020515257 A5 JP 2020515257A5
- Authority
- JP
- Japan
- Prior art keywords
- til
- til population
- population
- expansion culture
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 171
- 238000000034 method Methods 0.000 claims 58
- 206010028980 Neoplasm Diseases 0.000 claims 38
- 239000000203 mixture Substances 0.000 claims 30
- 230000007704 transition Effects 0.000 claims 28
- 230000001225 therapeutic effect Effects 0.000 claims 23
- 238000001802 infusion Methods 0.000 claims 18
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 17
- 108010002350 Interleukin-2 Proteins 0.000 claims 16
- 239000006143 cell culture medium Substances 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 14
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 12
- 238000012258 culturing Methods 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 7
- 238000005138 cryopreservation Methods 0.000 claims 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 6
- 108010074328 Interferon-gamma Proteins 0.000 claims 6
- 102100037850 Interferon gamma Human genes 0.000 claims 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 5
- 230000002338 cryopreservative effect Effects 0.000 claims 4
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 4
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 239000002609 medium Substances 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 208000021039 metastatic melanoma Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 241000701806 Human papillomavirus Species 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 239000012595 freezing medium Substances 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022173682A JP7772680B2 (ja) | 2017-03-29 | 2022-10-28 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
| JP2022173684A JP7817138B2 (ja) | 2017-03-29 | 2022-10-28 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
| JP2022173683A JP7814287B2 (ja) | 2017-03-29 | 2022-10-28 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
| JP2024187597A JP2025023951A (ja) | 2017-03-29 | 2024-10-24 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762478506P | 2017-03-29 | 2017-03-29 | |
| US62/478,506 | 2017-03-29 | ||
| US201762539410P | 2017-07-31 | 2017-07-31 | |
| US62/539,410 | 2017-07-31 | ||
| US201762548306P | 2017-08-21 | 2017-08-21 | |
| US62/548,306 | 2017-08-21 | ||
| US201762554538P | 2017-09-05 | 2017-09-05 | |
| US62/554,538 | 2017-09-05 | ||
| US201762559374P | 2017-09-15 | 2017-09-15 | |
| US62/559,374 | 2017-09-15 | ||
| US201762567121P | 2017-10-02 | 2017-10-02 | |
| US62/567,121 | 2017-10-02 | ||
| US201762577655P | 2017-10-26 | 2017-10-26 | |
| US62/577,655 | 2017-10-26 | ||
| US201762582874P | 2017-11-07 | 2017-11-07 | |
| US62/582,874 | 2017-11-07 | ||
| US201762596374P | 2017-12-08 | 2017-12-08 | |
| US62/596,374 | 2017-12-08 | ||
| PCT/US2018/012633 WO2018182817A1 (en) | 2017-03-29 | 2018-01-05 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173684A Division JP7817138B2 (ja) | 2017-03-29 | 2022-10-28 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
| JP2022173682A Division JP7772680B2 (ja) | 2017-03-29 | 2022-10-28 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
| JP2022173683A Division JP7814287B2 (ja) | 2017-03-29 | 2022-10-28 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515257A JP2020515257A (ja) | 2020-05-28 |
| JP2020515257A5 true JP2020515257A5 (enExample) | 2021-02-18 |
| JP7169291B2 JP7169291B2 (ja) | 2022-11-10 |
Family
ID=61569356
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553050A Active JP7169291B2 (ja) | 2017-03-29 | 2018-01-05 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
| JP2020552291A Active JP7522037B2 (ja) | 2017-03-29 | 2018-06-29 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用 |
| JP2022173683A Active JP7814287B2 (ja) | 2017-03-29 | 2022-10-28 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
| JP2022173684A Active JP7817138B2 (ja) | 2017-03-29 | 2022-10-28 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
| JP2022173682A Active JP7772680B2 (ja) | 2017-03-29 | 2022-10-28 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
| JP2024187597A Pending JP2025023951A (ja) | 2017-03-29 | 2024-10-24 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020552291A Active JP7522037B2 (ja) | 2017-03-29 | 2018-06-29 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用 |
| JP2022173683A Active JP7814287B2 (ja) | 2017-03-29 | 2022-10-28 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
| JP2022173684A Active JP7817138B2 (ja) | 2017-03-29 | 2022-10-28 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
| JP2022173682A Active JP7772680B2 (ja) | 2017-03-29 | 2022-10-28 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
| JP2024187597A Pending JP2025023951A (ja) | 2017-03-29 | 2024-10-24 | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法 |
Country Status (37)
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3628322A1 (en) | 2013-03-01 | 2020-04-01 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer |
| GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| HUE066460T2 (hu) * | 2016-10-26 | 2024-08-28 | Iovance Biotherapeutics Inc | A kriokonzervált tumor infiltráló limfociták restimulációja |
| US11332713B2 (en) | 2016-11-16 | 2022-05-17 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| CA3049165A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| AR112072A1 (es) | 2017-06-05 | 2019-09-18 | Iovance Biotherapeutics Inc | Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario |
| CR20200251A (es) * | 2017-11-17 | 2020-07-17 | Iovance Biotherapeutics Inc | Expansión de til de aspirados con aguja fina y biopsias por punción |
| KR102777151B1 (ko) | 2017-11-21 | 2025-03-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인터루킨-2의 부분 효능제 |
| EP3714041A1 (en) | 2017-11-22 | 2020-09-30 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| EP3737743A1 (en) | 2018-01-08 | 2020-11-18 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| CN112040986A (zh) | 2018-03-15 | 2020-12-04 | Ksq治疗公司 | 用于改进的免疫疗法的基因调控组合物和方法 |
| US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| CA3094957A1 (en) * | 2018-03-29 | 2019-10-03 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2019210131A1 (en) | 2018-04-27 | 2019-10-31 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2019217753A1 (en) * | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| MY210603A (en) * | 2018-11-05 | 2025-10-01 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| WO2020096927A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
| US12611427B2 (en) | 2018-11-05 | 2026-04-28 | Iovance Biotherapeutics, Inc. | Treatment of NSCLC patients refractory for anti-PD-1 antibody |
| JP7854297B2 (ja) * | 2018-11-05 | 2026-05-01 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 改良された腫瘍反応性ｔ細胞の選択 |
| CN113423820A (zh) * | 2018-11-08 | 2021-09-21 | 伽马三角洲疗法有限公司 | 分离和扩增细胞的方法 |
| CA3123392A1 (en) * | 2018-12-19 | 2020-06-25 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
| WO2020146740A1 (en) | 2019-01-10 | 2020-07-16 | Iovance Biotherapeutics, Inc. | System and methods for monitoring adoptive cell therapy clonality and persistence |
| US12582722B2 (en) | 2019-02-13 | 2026-03-24 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| US20220257656A1 (en) * | 2019-07-10 | 2022-08-18 | National Cancer Center | Specific marker for identifying t cells specifically attacking cancer cells |
| GB201911066D0 (en) | 2019-08-02 | 2019-09-18 | Achilles Therapeutics Ltd | T cell therapy |
| WO2021030482A1 (en) * | 2019-08-12 | 2021-02-18 | Bellicum Pharmaceuticals, Inc. | Improved formulations for immune cells |
| AU2020334237B2 (en) | 2019-08-19 | 2025-11-13 | Universität Basel | Cell therapy methods |
| EP4034140A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for use in adoptive cell therapy |
| EP4048295A1 (en) * | 2019-10-25 | 2022-08-31 | Iovance Biotherapeutics, Inc. | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| US12516291B2 (en) | 2019-12-11 | 2026-01-06 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same |
| BR112022011795A2 (pt) * | 2019-12-20 | 2022-08-30 | Instil Bio Uk Ltd | Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos |
| WO2021146436A2 (en) | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| CN115997008A (zh) * | 2020-04-22 | 2023-04-21 | 艾欧凡斯生物治疗公司 | 协调用于患者特异性免疫疗法的细胞的制造的系统和方法 |
| CN115461062A (zh) | 2020-04-28 | 2022-12-09 | 阿基里斯治疗英国有限公司 | T细胞疗法 |
| CA3158133A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CN116018158A (zh) * | 2020-04-30 | 2023-04-25 | 转化基因组学研究所 | 新抗原知情的肿瘤浸润性淋巴细胞癌免疫疗法 |
| CA3177413A1 (en) * | 2020-05-04 | 2021-11-11 | Michelle SIMPSON-ABELSON | Selection of improved tumor reactive t-cells |
| CA3176826A1 (en) | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| GB202006989D0 (en) * | 2020-05-12 | 2020-06-24 | Gammadelta Therapeutics Ltd | Methods for isolating gamma delta t cells |
| EP4159843A4 (en) * | 2020-05-29 | 2024-07-31 | Shanghai Juncell Therapeutics Co., Ltd. | MEDIUM FOR SEEDING CELLS OF TUMOR INFILTRATING LYMPHOCYTES AND ITS APPLICATION |
| CN111876381A (zh) * | 2020-07-22 | 2020-11-03 | 中美冠科生物技术（太仓）有限公司 | 一种t细胞模型及其在体外人源pd-1抗体药效评价中的应用 |
| JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療 |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| TW202237824A (zh) | 2020-11-23 | 2022-10-01 | 美商萊爾免疫藥物股份有限公司 | 培養免疫細胞之方法 |
| JP2024501127A (ja) | 2020-11-25 | 2024-01-11 | 上海君賽生物科技有限公司 | 腫瘍浸潤リンパ球培地及びその使用 |
| CN116761606A (zh) | 2020-11-25 | 2023-09-15 | 上海君赛生物科技有限公司 | 增强细胞杀伤的药物组合物及其用途 |
| EP4259164A1 (en) * | 2020-12-11 | 2023-10-18 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
| AU2021401302A1 (en) * | 2020-12-17 | 2023-07-06 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| EP4262827A1 (en) | 2020-12-17 | 2023-10-25 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
| JP2023554425A (ja) * | 2020-12-18 | 2023-12-27 | インスティル バイオ （ユーケイ） リミテッド | 腫瘍浸潤リンパ球の処理 |
| EP4263807A2 (en) * | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
| EP4262828A1 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| JP2024501845A (ja) | 2020-12-31 | 2024-01-16 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の自動化された産生のためのデバイス及びプロセス |
| CN114686430A (zh) * | 2020-12-31 | 2022-07-01 | 上海赛比曼生物科技有限公司 | 一种制备til的方法 |
| US20240052309A1 (en) * | 2021-01-04 | 2024-02-15 | Thyas Co. Ltd. | Method for producing regenerated t cell via ips cell |
| WO2022165260A1 (en) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
| CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
| EP4298208A1 (en) | 2021-02-25 | 2024-01-03 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| EP4301138A2 (en) | 2021-03-05 | 2024-01-10 | Iovance Biotherapeutics, Inc. | Tumor storage and cell culture compositions |
| US20240191191A1 (en) * | 2021-03-19 | 2024-06-13 | Iovance Biotherapeutics, Inc. | Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
| JP2024512029A (ja) | 2021-03-25 | 2024-03-18 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用 |
| KR102666931B1 (ko) * | 2021-03-30 | 2024-05-20 | 주식회사 네오젠티씨 | 면역세포 조성물을 생산하는 방법 |
| EP4320435A1 (en) | 2021-04-09 | 2024-02-14 | Achilles Therapeutics UK Limited | Batch release assay for pharmaceutical products relating to t cell therapies |
| GB202109886D0 (en) | 2021-07-08 | 2021-08-25 | Achilles Therapeutics Uk Ltd | Assay |
| CA3215830A1 (en) | 2021-04-19 | 2022-10-27 | Rafael CUBAS | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| CN117203328A (zh) | 2021-04-27 | 2023-12-08 | 武田药品工业株式会社 | 重组抗原呈递细胞 |
| JP2024519029A (ja) | 2021-05-17 | 2024-05-08 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用 |
| DE102021002748A1 (de) | 2021-05-27 | 2022-12-01 | Zellwerk Gmbh | Verfahren zur Herstellung von Tumor-infiltrierten T-Lymphozyten (TIL) und deren Verwendung als Zell-Therapeutika für die Behandlung humaner Tumoren |
| US20250090581A1 (en) * | 2021-06-17 | 2025-03-20 | CBio A/S | Multistep process for culturing tumor-infiltrating lymphocytes for therapeutic use |
| US20240287456A1 (en) | 2021-06-22 | 2024-08-29 | Achilles Therapeutics Uk Limited | A method for producing antigen-specific t cells |
| EP4373270A2 (en) | 2021-07-22 | 2024-05-29 | Iovance Biotherapeutics, Inc. | Method for cryopreservation of solid tumor fragments |
| JP2024527961A (ja) | 2021-07-28 | 2024-07-26 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療 |
| WO2023039488A1 (en) | 2021-09-09 | 2023-03-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
| US20250000903A1 (en) | 2021-09-24 | 2025-01-02 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
| CA3236073A1 (en) | 2021-10-26 | 2023-05-04 | Robert J. Brown | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| WO2023077015A2 (en) | 2021-10-27 | 2023-05-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| KR20240099331A (ko) | 2021-10-28 | 2024-06-28 | 라이엘 이뮤노파마, 인크. | 면역 세포를 배양하기 위한 방법 |
| CA3237410A1 (en) | 2021-11-10 | 2023-05-19 | Friedrich Graf Finck VON FINCKENSTEIN | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| US20250154503A1 (en) | 2022-01-14 | 2025-05-15 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
| US20250134999A1 (en) | 2022-01-14 | 2025-05-01 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
| EP4469065A1 (en) | 2022-01-28 | 2024-12-04 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| CA3243416A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | TUMOR INFILTRATION LYMPHOCYTES MODIFIED TO EXPRESS PAYLOADS |
| WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| JP2025512401A (ja) | 2022-04-15 | 2025-04-17 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス |
| CA3251533A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | TREATMENT OF CANCER PATIENTS WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST |
| WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
| GB202210006D0 (en) | 2022-07-07 | 2022-08-24 | Achilles Therapeutics Uk Ltd | Analysis of T cell samples |
| US20260021181A1 (en) | 2022-08-01 | 2026-01-22 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| EP4583890A1 (en) | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| EP4583889A1 (en) | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| US12181192B2 (en) * | 2022-09-16 | 2024-12-31 | Black & Decker, Inc. | Methods and devices for controlling the temperature of a surface |
| WO2024064642A2 (en) | 2022-09-19 | 2024-03-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for modulating t cell function |
| EP4612277A1 (en) | 2022-11-04 | 2025-09-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
| JP2025539712A (ja) | 2022-11-21 | 2025-12-09 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 遺伝子編集されたｔ細胞の増殖能を評価するための方法 |
| JP2025539816A (ja) | 2022-11-21 | 2025-12-09 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法 |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| WO2024178397A2 (en) | 2023-02-24 | 2024-08-29 | Elevatebio Technologies, Inc. | Modified immune effector cells and methods of use |
| DE102023002417B3 (de) | 2023-06-15 | 2024-12-05 | Zellwerk Gmbh | Verfahren zur Expansion von Zellen |
| WO2025006811A1 (en) | 2023-06-27 | 2025-01-02 | Lyell Immunopharma, Inc. | Methods for culturing immune cells |
| WO2025015318A2 (en) | 2023-07-13 | 2025-01-16 | Iovance Biotherapeutics, Inc. | Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes |
| WO2025029840A1 (en) | 2023-07-31 | 2025-02-06 | Tune Therapeutics, Inc. | Compositions and methods for multiplexed activation and repression of t cell gene expression |
| CN121909284A (zh) | 2023-07-31 | 2026-04-21 | 图恩疗法股份有限公司 | 用于调节il-2基因表达的组合物和方法 |
| WO2025038289A1 (en) * | 2023-08-17 | 2025-02-20 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Using 12 chemokine signature to select sting agonist and til treatments for solid tumors |
| CN121773331A (zh) * | 2023-08-31 | 2026-03-31 | 国立大学法人筑波大学 | 对肿瘤性滤泡调节性t细胞及肿瘤性滤泡杀伤性t细胞进行定量的方法、对肿瘤性滤泡调节性t细胞及肿瘤性滤泡杀伤性t细胞进行筛选的方法、治疗用组合物及试剂盒 |
| WO2025054540A1 (en) | 2023-09-08 | 2025-03-13 | Iovance Biotherapeutics, Inc. | Methods of gene-editing using programmable nucleases |
| WO2025101484A1 (en) | 2023-11-06 | 2025-05-15 | Iovance Biotherapeutics, Inc. | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies |
| WO2025256538A1 (zh) * | 2024-06-12 | 2025-12-18 | 北京沙砾生物医药股份有限公司 | 一种细胞产品中检测肿瘤残留的方法 |
| WO2026006604A1 (en) | 2024-06-26 | 2026-01-02 | Lyell Immunopharma, Inc. | Feeder cell replacement |
| CN118710478B (zh) * | 2024-08-27 | 2025-01-03 | 福州大学 | 基于改进麻雀搜索算法的地铁突发运营中断客流疏运方法 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| WO1988000970A2 (en) | 1986-08-08 | 1988-02-11 | Regents Of The University Of Minnesota | Method of culturing leukocytes |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US7479269B2 (en) | 1988-11-23 | 2009-01-20 | Genetics Institute, Llc | Methods for selectively enriching TH1 and TH2 cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| CN1507357A (zh) | 2000-10-31 | 2004-06-23 | PRҩƷ����˾ | 提高生物活性分子传递的方法和组合物 |
| US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| ES2422193T3 (es) | 2002-06-28 | 2013-09-09 | Life Technologies Corp | Métodos para restaurar el repertorio inmune en pacientes con defectos inmunológicos relacionados con la autoinmunidad y trasplante de órganos o de células madre hematopoyéticas |
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| ITMI20022118A1 (it) | 2002-10-04 | 2004-04-05 | Abiogen Pharma Spa | Procedimento per la coltura su larga scala di t-linfociti in un sistema omogeneo. |
| CN101120083B (zh) | 2003-10-08 | 2013-03-27 | 威尔森沃尔夫制造公司 | 利用透气性材料进行细胞培养的方法及装置 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| AU2006328945B2 (en) | 2005-12-21 | 2011-06-30 | Sentoclone International Ab | Method for treating malignant melanoma |
| US8211425B2 (en) | 2005-12-21 | 2012-07-03 | Sentoclone International Ab | Method for treating disseminated cancer |
| US8007785B2 (en) | 2005-12-21 | 2011-08-30 | Sentoclone International Ab | Method for treating colon cancer with tumour-reactive T-lymphocytes |
| CA2634167C (en) | 2005-12-21 | 2015-06-16 | Sentoclone Ab | Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer |
| FR2911346B1 (fr) * | 2007-01-12 | 2012-12-07 | Ct Hospitalier Universitaire De Nantes | Procede de culture in vitro de lymphocytes t,en particulier de lymphocytes t infiltrant les tumeurs dits til |
| US7951365B2 (en) | 2007-06-27 | 2011-05-31 | Deifiera Falun Ab | Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types |
| EP2203746B1 (en) * | 2007-09-24 | 2013-03-06 | Technion Research & Development Foundation Ltd. | T cell subpopulations capable of treating cancer |
| WO2014085437A2 (en) | 2012-11-27 | 2014-06-05 | The Johns Hopkins University | Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity |
| US20150320798A1 (en) | 2012-11-27 | 2015-11-12 | The Johns Hopkins University | Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
| EP2510086A4 (en) | 2009-12-08 | 2013-05-22 | Wolf Wilson Mfg Corp | IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES |
| US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
| WO2012065086A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| CN103502439B (zh) | 2011-04-13 | 2016-10-12 | 因缪尼卡姆股份公司 | 用于抗原特异性t细胞增殖的方法 |
| PL2768939T3 (pl) * | 2011-10-21 | 2017-02-28 | Cell Medica Limited | Urządzenie do aseptycznego rozwoju komórek |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| CN102816734A (zh) | 2012-05-09 | 2012-12-12 | 阮润生 | 一种肿瘤抗原特异性t细胞的获取方法 |
| EP2850175B1 (en) | 2012-05-18 | 2020-12-16 | Wilson Wolf Manufacturing Corporation | Improved methods of cell culture for adoptive cell therapy |
| EP2859093A4 (en) | 2012-06-11 | 2016-08-17 | Wolf Wilson Mfg Corp | IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES |
| EP2961415B1 (en) | 2013-03-01 | 2021-01-06 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing enriched populations of tumor-reactive t cells from tumor |
| EP3628322A1 (en) | 2013-03-01 | 2020-04-01 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer |
| CN118562610A (zh) | 2013-06-24 | 2024-08-30 | 威尔逊沃夫制造公司 | 用于透气性细胞培养过程的封闭系统装置和方法 |
| ES2932429T3 (es) * | 2013-07-15 | 2023-01-19 | Us Health | Métodos de preparación de células T anti-antígeno de virus del papiloma humano |
| US10233425B2 (en) | 2013-09-16 | 2019-03-19 | The Trustees Of The University Of Pennsylvania | CD137 enrichment for efficient tumor infiltrating lymphocyte selection |
| AU2015231041B2 (en) | 2014-03-20 | 2020-07-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor-infiltrating lymphocytes for adoptive cell therapy |
| WO2015157636A1 (en) | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
| CA2946312A1 (en) * | 2014-04-23 | 2015-10-29 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| RU2739770C2 (ru) | 2014-06-11 | 2020-12-28 | полибайосепт ГмбХ | Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии |
| WO2015188839A2 (en) | 2014-06-13 | 2015-12-17 | Immudex Aps | General detection and isolation of specific cells by binding of labeled molecules |
| WO2016037054A1 (en) | 2014-09-04 | 2016-03-10 | The Johns Hopkins University | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions |
| AU2014407539B2 (en) * | 2014-10-02 | 2020-10-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation |
| EP3034092A1 (en) | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
| WO2016179006A1 (en) | 2015-05-01 | 2016-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| FR3040396A1 (fr) | 2015-06-30 | 2017-03-03 | Chu Nantes | Procede de cryoconservation de lymphocytes infiltrant la tumeur |
| FR3038324B1 (fr) | 2015-06-30 | 2020-10-30 | Lab Francais Du Fractionnement | Procede de cryoconservation de cellules a visee therapeutique |
| WO2017048614A1 (en) | 2015-09-15 | 2017-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood |
| AU2016341529B2 (en) | 2015-10-22 | 2023-03-30 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| IL258935B2 (en) | 2015-10-28 | 2024-08-01 | Life Tech As | Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio |
| MX2019000180A (es) | 2016-06-28 | 2019-11-05 | Geneius Biotechnology Inc | Composiciones de células t para la inmunoterapia. |
| CN106244538A (zh) | 2016-08-04 | 2016-12-21 | 英普乐孚生物技术(上海)有限公司 | 一种恶性腹水来源的til细胞的分离培养方法 |
| MY192158A (en) | 2016-09-14 | 2022-08-03 | Abbvie Biotherapeutics Inc | Anti-pd-1 antibodies and their uses |
| HUE066460T2 (hu) | 2016-10-26 | 2024-08-28 | Iovance Biotherapeutics Inc | A kriokonzervált tumor infiltráló limfociták restimulációja |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| KR102618948B1 (ko) | 2016-11-17 | 2023-12-27 | 이오반스 바이오테라퓨틱스, 인크. | 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법 |
| US20200095547A1 (en) | 2016-12-02 | 2020-03-26 | Darya ALIZADEH | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors |
| CN106591232A (zh) | 2017-01-04 | 2017-04-26 | 安徽安龙基因医学检验所有限公司 | 一种高效的pd‑1‑cd8+t细胞的培养方法 |
| MX2019007963A (es) | 2017-01-06 | 2019-10-21 | Iovance Biotherapeutics Inc | Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf. |
| CA3049165A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| MX2019010906A (es) | 2017-03-14 | 2020-02-12 | Juno Therapeutics Inc | Metodos para almacenamiento criogenico. |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| KR20200003913A (ko) | 2017-05-10 | 2020-01-10 | 이오반스 바이오테라퓨틱스, 인크. | 액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도 |
| AR112072A1 (es) | 2017-06-05 | 2019-09-18 | Iovance Biotherapeutics Inc | Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario |
| CN107384867B (zh) | 2017-08-04 | 2020-09-11 | 北京世纪劲得生物技术有限公司 | 一种肿瘤组织til细胞制备方法及专用培养基 |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| CN115997008A (zh) | 2020-04-22 | 2023-04-21 | 艾欧凡斯生物治疗公司 | 协调用于患者特异性免疫疗法的细胞的制造的系统和方法 |
-
2017
- 2017-06-16 JO JOP/2019/0224A patent/JOP20190224A1/ar unknown
-
2018
- 2018-01-05 EP EP23195819.0A patent/EP4279574A3/en active Pending
- 2018-01-05 NZ NZ796152A patent/NZ796152A/en unknown
- 2018-01-05 ES ES18709132T patent/ES2874335T3/es active Active
- 2018-01-05 SI SI201830278T patent/SI3601533T1/sl unknown
- 2018-01-05 TN TNP/2019/000273A patent/TN2019000273A1/en unknown
- 2018-01-05 JP JP2019553050A patent/JP7169291B2/ja active Active
- 2018-01-05 ES ES20161276T patent/ES3008832T3/es active Active
- 2018-01-05 MX MX2019011768A patent/MX2019011768A/es unknown
- 2018-01-05 PE PE2019001976A patent/PE20191841A1/es unknown
- 2018-01-05 PL PL20161276.9T patent/PL3722415T3/pl unknown
- 2018-01-05 RS RS20250044A patent/RS66400B1/sr unknown
- 2018-01-05 PT PT201612769T patent/PT3722415T/pt unknown
- 2018-01-05 KR KR1020247023861A patent/KR20240114787A/ko active Pending
- 2018-01-05 EP EP21175134.2A patent/EP3910055A1/en active Pending
- 2018-01-05 MD MDE20200116T patent/MD3601533T2/ro unknown
- 2018-01-05 SI SI201831186T patent/SI3730608T1/sl unknown
- 2018-01-05 PL PL18709132T patent/PL3601533T3/pl unknown
- 2018-01-05 DK DK18709132.7T patent/DK3601533T3/da active
- 2018-01-05 UA UAA201910623A patent/UA130566C2/uk unknown
- 2018-01-05 SM SM20250027T patent/SMT202500027T1/it unknown
- 2018-01-05 EP EP20161179.5A patent/EP3730608B1/en active Active
- 2018-01-05 LT LTEP20161179.5T patent/LT3730608T/lt unknown
- 2018-01-05 RS RS20210622A patent/RS61863B1/sr unknown
- 2018-01-05 DK DK20161276.9T patent/DK3722415T3/da active
- 2018-01-05 HR HRP20241688TT patent/HRP20241688T1/hr unknown
- 2018-01-05 HU HUE18709132A patent/HUE054829T2/hu unknown
- 2018-01-05 PT PT187091327T patent/PT3601533T/pt unknown
- 2018-01-05 IL IL305198A patent/IL305198A/en unknown
- 2018-01-05 MD MDE20201056T patent/MD3722415T2/ro unknown
- 2018-01-05 BR BR112019020326A patent/BR112019020326A2/pt unknown
- 2018-01-05 KR KR1020197031407A patent/KR102686794B1/ko active Active
- 2018-01-05 EP EP18709132.7A patent/EP3601533B1/en active Active
- 2018-01-05 SM SM20210298T patent/SMT202100298T1/it unknown
- 2018-01-05 MA MA68598A patent/MA68598B1/fr unknown
- 2018-01-05 ES ES20161179T patent/ES3009885T3/es active Active
- 2018-01-05 HR HRP20250068TT patent/HRP20250068T1/hr unknown
- 2018-01-05 FI FIEP20161179.5T patent/FI3730608T3/fi active
- 2018-01-05 PL PL20161179.5T patent/PL3730608T3/pl unknown
- 2018-01-05 US US15/863,634 patent/US10894063B2/en active Active
- 2018-01-05 PT PT201611795T patent/PT3730608T/pt unknown
- 2018-01-05 MD MDE20201130T patent/MD3730608T2/ro unknown
- 2018-01-05 AU AU2018243355A patent/AU2018243355B2/en active Active
- 2018-01-05 FI FIEP20161276.9T patent/FI3722415T3/fi active
- 2018-01-05 EP EP20183493.4A patent/EP3766964A1/en active Pending
- 2018-01-05 SM SM20250040T patent/SMT202500040T1/it unknown
- 2018-01-05 WO PCT/US2018/012633 patent/WO2018182817A1/en not_active Ceased
- 2018-01-05 LT LTEP18709132.7T patent/LT3601533T/lt unknown
- 2018-01-05 CA CA3057975A patent/CA3057975A1/en active Pending
- 2018-01-05 NZ NZ796142A patent/NZ796142A/en unknown
- 2018-01-05 HU HUE20161276A patent/HUE070256T2/hu unknown
- 2018-01-05 MA MA68856A patent/MA68856B1/fr unknown
- 2018-01-05 CN CN201880035181.8A patent/CN110785486A/zh active Pending
- 2018-01-05 LT LTEP20161276.9T patent/LT3722415T/lt unknown
- 2018-01-05 SI SI201831203T patent/SI3722415T1/sl unknown
- 2018-01-05 RS RS20250109A patent/RS66452B1/sr unknown
- 2018-01-05 CR CR20190487A patent/CR20190487A/es unknown
- 2018-01-05 EP EP20161276.9A patent/EP3722415B1/en active Active
- 2018-01-05 SG SG11201908994R patent/SG11201908994RA/en unknown
- 2018-01-05 TW TW107100568A patent/TWI799402B/zh active
- 2018-01-05 HR HRP20210677TT patent/HRP20210677T1/hr unknown
- 2018-01-05 HU HUE20161179A patent/HUE070176T2/hu unknown
- 2018-01-05 DK DK20161179.5T patent/DK3730608T3/da active
- 2018-01-18 US US15/874,718 patent/US10166257B2/en active Active
- 2018-02-08 US US15/892,311 patent/US10130659B2/en active Active
- 2018-03-29 US US15/940,901 patent/US10918666B2/en active Active
- 2018-06-29 JP JP2020552291A patent/JP7522037B2/ja active Active
- 2018-06-29 US US17/041,305 patent/US12121541B2/en active Active
- 2018-09-19 US US16/136,147 patent/US10272113B2/en active Active
- 2018-09-19 US US16/136,157 patent/US10420799B2/en active Active
- 2018-11-15 US US16/192,707 patent/US10537595B2/en active Active
- 2018-11-27 US US16/201,957 patent/US10398734B2/en active Active
- 2018-11-28 US US16/203,467 patent/US10463697B2/en active Active
- 2018-11-28 US US16/203,478 patent/US10363273B2/en active Active
-
2019
- 2019-05-29 US US16/425,767 patent/US10695372B2/en active Active
- 2019-05-29 US US16/425,778 patent/US10646517B2/en active Active
- 2019-05-29 US US16/425,746 patent/US10639330B2/en active Active
- 2019-09-23 IL IL26954319A patent/IL269543A/en unknown
- 2019-09-27 PH PH12019502247A patent/PH12019502247A1/en unknown
- 2019-09-27 CL CL2019002769A patent/CL2019002769A1/es unknown
- 2019-09-30 MX MX2024002827A patent/MX2024002827A/es unknown
- 2019-10-28 CO CONC2019/0011995A patent/CO2019011995A2/es unknown
- 2019-10-29 EC ECSENADI201977884A patent/ECSP19077884A/es unknown
-
2020
- 2020-01-17 US US16/746,416 patent/US10653723B1/en active Active
- 2020-04-14 US US16/848,386 patent/US10953046B2/en active Active
- 2020-04-14 US US16/848,426 patent/US10953047B2/en active Active
- 2020-04-14 US US16/848,454 patent/US10946044B2/en active Active
- 2020-04-14 US US16/848,361 patent/US10905718B2/en active Active
- 2020-04-14 US US16/848,442 patent/US10933094B2/en active Active
- 2020-04-14 US US16/848,474 patent/US10946045B2/en active Active
- 2020-05-20 US US16/879,711 patent/US10925900B2/en active Active
- 2020-10-22 CL CL2020002737A patent/CL2020002737A1/es unknown
- 2020-12-02 US US17/110,179 patent/US12611428B2/en active Active
- 2020-12-02 US US17/110,207 patent/US11083752B2/en active Active
- 2020-12-18 US US17/127,840 patent/US11052116B2/en active Active
- 2020-12-18 US US17/127,795 patent/US11052115B2/en active Active
- 2020-12-18 US US17/127,768 patent/US11007225B1/en active Active
- 2020-12-18 US US17/127,790 patent/US11007226B2/en active Active
-
2021
- 2021-01-12 US US17/147,080 patent/US20210128623A1/en active Pending
- 2021-01-12 US US17/147,090 patent/US11040070B2/en active Active
- 2021-01-12 US US17/147,096 patent/US12226434B2/en active Active
- 2021-01-12 US US17/147,412 patent/US20210214685A1/en active Pending
- 2021-01-12 US US17/147,073 patent/US11013770B1/en active Active
- 2021-01-13 US US17/148,475 patent/US11168303B2/en active Active
- 2021-01-13 US US17/148,508 patent/US11168304B2/en active Active
- 2021-05-14 CY CY20211100416T patent/CY1124136T1/el unknown
- 2021-05-20 US US17/326,088 patent/US11202803B1/en active Active
- 2021-07-22 US US17/383,280 patent/US11304979B2/en active Active
- 2021-07-22 US US17/383,276 patent/US11273180B2/en active Active
- 2021-07-22 US US17/383,272 patent/US11202804B2/en active Active
- 2021-07-22 US US17/382,831 patent/US11241456B2/en active Active
- 2021-09-21 US US17/480,596 patent/US11337998B2/en active Active
- 2021-09-21 US US17/480,534 patent/US11291687B2/en active Active
- 2021-09-21 US US17/480,587 patent/US11344579B2/en active Active
- 2021-09-21 US US17/480,525 patent/US11273181B2/en active Active
-
2022
- 2022-07-01 US US17/856,806 patent/US20230133298A1/en active Pending
- 2022-07-01 US US17/856,800 patent/US11517592B1/en active Active
- 2022-07-01 US US17/856,793 patent/US20230015649A1/en active Pending
- 2022-08-03 US US17/817,273 patent/US20230045899A1/en active Pending
- 2022-08-03 US US17/817,247 patent/US12611429B2/en active Active
- 2022-08-03 US US17/817,276 patent/US20220387498A1/en active Pending
- 2022-08-03 US US17/817,226 patent/US12558375B2/en active Active
- 2022-08-03 US US17/817,217 patent/US20220395533A1/en active Pending
- 2022-08-03 US US17/817,207 patent/US12194061B2/en active Active
- 2022-08-03 US US17/817,239 patent/US20230012086A1/en active Pending
- 2022-08-03 US US17/817,232 patent/US11998568B2/en active Active
- 2022-08-03 US US17/817,281 patent/US11529372B1/en active Active
- 2022-08-03 US US17/817,279 patent/US11541077B2/en active Active
- 2022-10-28 JP JP2022173683A patent/JP7814287B2/ja active Active
- 2022-10-28 JP JP2022173684A patent/JP7817138B2/ja active Active
- 2022-10-28 JP JP2022173682A patent/JP7772680B2/ja active Active
-
2024
- 2024-10-24 JP JP2024187597A patent/JP2025023951A/ja active Pending
- 2024-11-22 US US18/957,327 patent/US12485145B2/en active Active
- 2024-12-17 US US18/984,525 patent/US20250121008A1/en active Pending
- 2024-12-17 US US18/984,595 patent/US20250121009A1/en active Pending
-
2025
- 2025-01-22 AU AU2025200434A patent/AU2025200434A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515257A5 (enExample) | ||
| JP2021503281A5 (enExample) | ||
| Shapiro et al. | Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse | |
| JP2022506586A5 (enExample) | ||
| IL274584B1 (en) | Til expansion from fine needle aspirates and small biopsies | |
| Shi et al. | Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer | |
| CN120733046A (zh) | 用于治疗胰腺癌的药物组合物 | |
| Ramos et al. | Allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B-cell malignancies: an interim analysis | |
| Schwinger et al. | Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients | |
| JP2017524031A (ja) | ガンマデルタｔ細胞およびその使用 | |
| FI3843759T3 (fi) | Tuumoriin filtroituvien lymfosyyttien käyttö anti-PD-1-vasta-aineelle vastustuskykyisten NSCLC-potilaiden hoitoon | |
| Zhu et al. | A clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancer | |
| JP2022512899A5 (enExample) | ||
| JP2021535128A5 (enExample) | ||
| AU2006288348A1 (en) | Method for activation treatment of antigen-presenting cell | |
| KR20200135936A (ko) | 전립선 암 특이적 골수 침윤성 림프구 및 이의 용도 | |
| CN106795493A (zh) | 使用双膦酸盐、抗cd3抗体和il‑2扩增t细胞群体 | |
| KR20210028675A (ko) | 제대혈로부터 cik nkt 세포의 생성 | |
| Wang et al. | Cooperation of CD4+ T cells and CD8+ T cells and release of IFN-γ are critical for antileukemia responses of recipient mice treated by microtransplantation | |
| EP2878666B1 (en) | Industrial preparation of natural killer cells (nks) and injection using human allogeneic karyocytes | |
| JP2001314183A (ja) | キラー活性を増強したリンパ球 | |
| CN108245673A (zh) | 表达Th1特性和溶细胞性质的细胞 | |
| Meehan et al. | Adoptive cellular therapy using cells enriched for NKG2D+ CD3+ CD8+ T cells after autologous transplantation for myeloma | |
| CN106955352A (zh) | 一种用于治疗癌症的药物组合物和试剂盒 | |
| CN120078889A (zh) | 用于治疗胰腺癌的药物组合物 |